HIF1A and type 2 diabetes mellitus: These studies establish HIF-1α as a potential therapeutic target for PIO (approved for clinical use in the treatment of type 2 diabetes), which could mitigate the risk of developing respiratory infections in people with a history of alcohol use disorders.